patritumab deruxtecan(HER3-DXd)治疗EGFR突变非小细胞肺癌的U31402-A-U102研究:转化见解与总生存
U31402-A-U102是一项正在进行的I期研究,评估HER3-DXd在晚期NSCLC中的疗效。在既往接受EGFR TKI和铂类化疗后进展的EGFR突变NSCLC患者中,HER3-DXd 5.6 mg/kg每3周一次静脉给药,确认客观缓解率为41.0%,中位无进展生存期6.4个月,中位总生存期16.2个月。肿瘤生物标志物分析首次描述了HER3-DXd潜在耐药机制。
要点
- 在78例既往接受第三代EGFR TKI和铂类化疗的患者中,确认客观缓解率为41.0%。
- 中位无进展生存期为6.4个月,中位总生存期为16.2个月。
- 在肿瘤进展时鉴定出ERBB3和TOP1获得性突变,可能介导HER3-DXd耐药。
核心结论
- 在既往接受EGFR TKI和铂类化疗后的EGFR突变NSCLC患者中,HER3-DXd治疗与具有临床意义的总生存相关。
- 肿瘤生物标志物特征分析首次描述了HER3-DXd治疗的潜在耐药机制。
研究设计与样本
- U31402-A-U102是一项正在进行的I期研究,评估HER3-DXd在晚期NSCLC患者中的表现。
- 安全性在既往接受EGFR TKI且接受HER3-DXd 5.6 mg/kg静脉给药每3周一次的EGFR突变NSCLC患者中评估(N=102)。
- 疗效在同时既往接受铂类化疗的患者中评估。
主要发现
- 安全性人群中位治疗持续时间为5.5个月(范围0.7-27.5个月)。
- 安全性人群中76.5%的患者发生≥3级不良事件,总体安全性与既往报告一致。
- 在78/102例既往接受第三代EGFR TKI和铂类化疗的患者中,经盲态独立中心审查(按RECIST v1.1)确认客观缓解率为41.0%(95%CI 30.0%-52.7%)。
- 该78例患者的中位无进展生存期为6.4个月(95%CI 4.4-10.8),中位总生存期为16.2个月(95%CI 11.2-21.9)。
- 基线时患者具有多样的EGFR TKI耐药机制;肿瘤进展时鉴定出ERBB3和TOP1获得性突变,可能赋予对HER3-DXd的耐药性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Human epidermal growth factor receptor 3 (HER3) is broadly expressed in non-small-cell lung cancer (NSCLC) and is the target of patritumab deruxtecan (HER3-DXd), an antibody-drug conjugate consisting of a HER3 antibody attached to a topoisomerase I inhibitor payload via a tetrapeptide-based cleavable linker. U31402-A-U102 is an ongoing phase I study of HER3-DXd in patients with advanced NSCLC. Patients with epidermal growth factor receptor (EGFR)-mutated NSCLC that progressed after EGFR tyrosine kinase inhibitor (TKI) and platinum-based chemotherapy (PBC) who received HER3-DXd 5.6 mg/kg intravenously once every 3 weeks had a confirmed objective response rate (cORR) of 39%. We present median overall survival (OS) with extended follow-up in a larger population of patients with EGFR-mutated NSCLC and an exploratory analysis in those with acquired genomic alterations potentially associated with resistance to HER3-DXd. PATIENTS AND METHODS: Safety was assessed in patients with EGFR-mutated NSCLC previously treated with EGFR TKI who received HER3-DXd 5.6 mg/kg; efficacy was assessed in those who also had prior PBC. RESULTS: In the safety population (N = 102), median treatment duration was 5.5 (range 0.7-27.5) months. Grade ≥3 adverse events occurred in 76.5% of patients; the overall safety profile was consistent with previous reports. In 78/102 patients who had prior third-generation EGFR TKI and PBC, cORR by blinded independent central review (as per RECIST v1.1) was 41.0% [95% confidence interval (CI) 30.0% to 52.7%], median progression-free survival was 6.4 (95% CI 4.4-10.8) months, and median OS was 16.2 (95% CI 11.2-21.9) months. Patients had diverse mechanisms of EGFR TKI resistance at baseline. At tumor progression, acquired mutations in ERBB3 and TOP1 that might confer resistance to HER3-DXd were identified. CONCLUSIONS: In patients with EGFR-mutated NSCLC after EGFR TKI and PBC, HER3-DXd treatment was associated with a clinically meaningful OS. The tumor biomarker characterization comprised the first description of potential mechanisms of resistance to HER3-DXd therapy.
引用
- Yu HA, Baik C, Kim DW, et al. Translational insights and overall survival in the U31402-A-U102 study of patritumab deruxtecan (HER3-DXd) in EGFR-mutated NSCLC. Ann Oncol. 2024. PMID: 38369013. doi:10.1016/j.annonc.2024.02.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。